Services
Four disciplines. One operator at the table.
Four ways we partner with PE firms, DSOs, and healthcare platforms, from pre-acquisition diligence through turnaround and exit.
01 · PE Value Creation
What we do
Commercial due diligence is where most advisory relationships start. We evaluate clinical operations, revenue quality, payer mix, provider productivity, and growth runway, from the perspective of someone who has personally built and run these platforms. Post-close, we design and support 100-day value creation plans that translate the investment thesis into clinician-actionable KPIs, EBITDA acceleration playbooks, and operational benchmarking the clinical team actually follows.
Typical engagements
- Pre-acquisition commercial diligence
- 100-day value creation plans
- EBITDA acceleration playbooks
- Provider productivity optimization
- Payer/MCO negotiation strategy
- Board advisory and governance
Who it's for
PE firms and family offices with existing or prospective healthcare platform investments.
Trusted advisor across $250M+ in sourced and closed transactions. Collaborated on 2 platform deals (orthopedics, primary medicine) with combined enterprise value of $72M.
02 · DSO Growth Strategy
What we do
Growth in multi-site healthcare isn't just about adding locations. It's about building the operational infrastructure, revenue engine, and clinical talent strategy that makes each new site accretive, not dilutive. We design go-to-market strategies, de novo expansion playbooks, acquisition integration plans, and revenue optimization programs, across dental, home health, and physician services, from a single practice to 35 offices and from zero US presence to 28 enterprise accounts in 8 months.
Engagements & capabilities
- Go-to-market strategy
- De novo expansion planning
- Acquisition integration
- Revenue optimization
- Payer negotiations
- Clinical talent acquisition
Who it's for
DSOs and multi-site healthcare platforms looking to accelerate organic and inorganic growth.
At RipeGlobal, we built the US GTM engine from zero: $8.5M ARR in eight months, with 28 contracted enterprise accounts.
03 · Turnaround & Repositioning
What we do
We've walked into two platforms in decline and turned both around. The approach is the same: get to the root cause fast (it's almost never what the board thinks it is), stop the bleed, rebuild the revenue engine, and reposition for growth. We lead revenue recovery, operational restructuring, cost rationalization, provider productivity programs, payer renegotiation, and full rebrands when the market positioning has become a liability.
Typical engagements
- Revenue decline diagnosis & recovery
- Operational cost restructuring
- Provider productivity turnaround
- Payer/MCO renegotiation
- Brand repositioning and relaunch
- Cash flow stabilization
Who it's for
Underperforming healthcare platforms where revenue is declining, cash is burning, or the original thesis is at risk.
At dntl bar: 360% revenue growth in 7 months. At VIVA: reversed a 12% YoY decline, shifted burn to an EBITDA run-rate, and secured $25M in PE investment.
04 · Transaction Advisory
What we do
Transactions in healthcare services are uniquely complex. Valuation depends on revenue quality, provider retention risk, payer concentration, and a dozen clinical-operational factors that traditional investment bankers miss. We provide commercial diligence from the operator's seat, help sellers position platforms for premium multiples, source acquisition targets through our extensive network, and advise on post-close integration. Because we've been on both sides, as a founder who sold and an advisor who sources, we bring perspective that pure financial advisors can't.
Typical engagements
- Commercial diligence (buy & sell-side)
- Platform positioning for premium value
- Acquisition target sourcing
- Post-acquisition integration
- Clinician-founder advisory in M&A
- MSO/DSO structuring & governance
Who it's for
Healthcare platform founders, PE firms, and strategic acquirers navigating buy-side or sell-side transactions.
$250M+ in sourced and closed transactions. 2 platform deals (orthopedics, primary medicine) with combined $72M enterprise value.
Ready to discuss your platform?
Whether you're pre-acquisition, mid-turnaround, or ready to scale, we've been there. Let's talk about unlocking your clinical-operational growth plan.